Lung Cancer

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
  • Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Hodgkin's Lymphoma | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Phase I | Unknown Sites | Breast
  • Principal Investigator: Patricia LoRusso
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or LN-145) in Patients With Solid Tumors
  • Disease/Condition: Lung
  • Principal Investigator: Scott Gettinger
A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy
  • Disease/Condition: Lung
  • Principal Investigator: Anne Chiang
Determining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer
  • Disease/Condition: Lung
  • Principal Investigator: Scott Gettinger
Assessing the Feasibility of a Patient-centered Activity Regimen in Patients With Advanced Stage Lung Cancer
  • Disease/Condition: Lung
  • Principal Investigator: Brett Bade
A Phase I/Ib Study of APX005M in Combination With Nivolumab and Cabiralizumab in Patients With Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Whose Disease Has Progressed on Anti-PD- 1/PD-L1 Therapy
  • Disease/Condition: Lung | Melanoma, skin | Other Skin | Other Urinary
  • Principal Investigator: Harriet Kluger
A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
  • Disease/Condition: Lung
  • Principal Investigator: Sarah Goldberg
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (HuMax®-AXL-ADC) in Patients With Solid Tumors
  • Disease/Condition: Lung | Melanoma, skin | Other Skin
  • Principal Investigator: Mario Sznol
Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
  • Disease/Condition: Lung
  • Principal Investigator: Roy H. Decker
A Phase 1 Trial of MLN0128 (TAK-228) in Combination With Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
  • Disease/Condition: Lung
  • Principal Investigator: Sarah Goldberg